Pricing Log in Create free account

AIM ImmunoTech Inc. (AIM) vs Enveric Biosciences, Inc. (ENVB)

AIM ImmunoTech Inc. and Enveric Biosciences, Inc. are both Biotechnology companies. AIM ImmunoTech Inc. and Enveric Biosciences, Inc. are of similar size ($6.3M and $6.1M). Enveric Biosciences, Inc. grew revenue faster over the last twelve months: −13.9% against −21.5%. Enveric Biosciences, Inc. has the higher net margin (0.00% vs −15,021.1%) and the higher return on invested capital (0.00% vs 0.00%). Across the 16 metrics below, Enveric Biosciences, Inc. leads on 12 and AIM ImmunoTech Inc. on 4.

Valuation

Metric AIM ENVB Biotechnology median
P/E n/m n/m 10.60
P/S 28.83 0.16 9.40
P/B 0.35 0.70 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA 0.70 0.27 0.66
EV/Sales (71.38) (0.07) 9.02
Earnings yield (2,575.37%) (1,322.27%) (32.88%)
Free cash flow yield (533.84%) (188.36%) (23.13%)

Profitability

Metric AIM ENVB Biotechnology median
Gross margin (23.16%) 0.00% 68.51%
Operating margin (11,724.21%) 0.00% 0.00%
Net margin (15,021.05%) 0.00% 0.00%
Free cash flow margin (15,385.26%) 0.00% 0.00%
Return on equity (2,382.30%) (235.48%) (51.96%)
Return on assets (169.28%) (193.53%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric AIM ENVB Biotechnology median
Revenue growth (TTM) (21.49%) (13.93%) 6.76%
EPS growth (last fiscal year) 72.19% 84.14% 29.88%
Revenue growth, 5-year CAGR (11.60%) — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric AIM ENVB Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 2.11 10.21 4.97
Net debt to EBITDA 0.22 0.55 1.01

Dividend

Metric AIM ENVB Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric AIM ENVB Biotechnology median
Market cap 6.07m 6.26m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack